Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer--an update (Q36194631)

12 August 2017

1 reference

title

Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer--an update (English)

1 reference

12 August 2017

1 reference

Barnard DR

1

1 reference

12 August 2017

Woods WG

series ordinal

2

1 reference

12 August 2017

publication date

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

46

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

651-663

1 reference

Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Second cancers in survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Second neoplasms after acute lymphoblastic leukemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Second malignancy after treatment of childhood non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Myeloid neoplasia in children treated for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Proposals for the classification of the myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported i

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Role of the NF1 gene in leukemogenesis and myeloid growth control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Genetic predisposition and treatment-related leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Treatment of acute myeloid leukemia: state-of-the-art and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Clinical implications of the p53 tumor-suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Alterations of p53 and Rb genes in a novel human GM‐CSF‐dependent myeloid cell line (OHN‐GM) established from therapy‐related leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Chemotherapy of secondary leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

Targeted therapies for high-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190500051042

10.1080/10428190500051042

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference